Traders overwhelmingly back an 80–90 flu hospitalization rate per 100,000 population for week 11 (mid-March) 2026, with 96% market-implied probability, anchored by CDC historical FluView data showing cumulative rates averaging 82 per 100k by that point in moderate-severity seasons like 2018–19 and 2021–22. This reflects stable vaccination coverage around 45%, predictable H3N2 dominance with fair vaccine match, and waning post-peak dynamics as immunity builds. Recent 2023–24 mild season (cumulative ~45 per 100k) reinforces baseline expectations absent major shifts. Realistic challenges include persistent high population immunity driving below 60, or novel strain emergence/antigenic drift sparking 100+, tracked via CDC's fall 2025 surveillance onset.
Resumo experimental gerado por IA com dados do Polymarket · AtualizadoFlu Hospitalization Rate Week 11, 2026?
Flu Hospitalization Rate Week 11, 2026?
80–90 96.3%
90–100 4.3%
60–70 2.9%
70–80 2.6%
<60
2%
60–70
3%
70–80
3%
80–90
96%
90–100
4%
100+
2%
80–90 96.3%
90–100 4.3%
60–70 2.9%
70–80 2.6%
<60
2%
60–70
3%
70–80
3%
80–90
96%
90–100
4%
100+
2%
If the recorded data falls exactly between two brackets, this market will resolve to the higher bracket.
The resolution source for this market will be CDC FluView / FluSurv-NET (see: https://www.cdc.gov/fluview/index.html). If the FluSurv-NET hospitalization rate for the specified week is not released by 11:59 PM ET on the tenth calendar day following the date of the prior FluView weekly report release, this market will resolve to the lowest bracket.
Note: Only the CDC FluSurv-NET cumulative hospitalization rate per 100,000 population for the specified week will qualify, regardless of estimates, projections, state-level reports, or other influenza surveillance metrics published by the CDC or other sources.
Mercado Aberto: Mar 20, 2026, 2:29 PM ET
Resolver
0x69c47De9D...Resolver
0x69c47De9D...Traders overwhelmingly back an 80–90 flu hospitalization rate per 100,000 population for week 11 (mid-March) 2026, with 96% market-implied probability, anchored by CDC historical FluView data showing cumulative rates averaging 82 per 100k by that point in moderate-severity seasons like 2018–19 and 2021–22. This reflects stable vaccination coverage around 45%, predictable H3N2 dominance with fair vaccine match, and waning post-peak dynamics as immunity builds. Recent 2023–24 mild season (cumulative ~45 per 100k) reinforces baseline expectations absent major shifts. Realistic challenges include persistent high population immunity driving below 60, or novel strain emergence/antigenic drift sparking 100+, tracked via CDC's fall 2025 surveillance onset.
Resumo experimental gerado por IA com dados do Polymarket · Atualizado
Cuidado com os links externos.
Cuidado com os links externos.
Frequently Asked Questions